Type 2 diabetes A Risk Factor For Blood Cancers

A meta-analysis led by researchers at the Miriam Hospital and published in the journal Blood found that people with type 2 diabetes have an astonishing increased risk of developing hematologic malignancies including subtypes of non-Hodgkin lymphoma, some leukemias, and myeloma.

These findings add to a small but growing database that associates adult onset type 2 diabetes with the development of some cancers.

Type 2 diabetes has previously been associated with pancreatic cancer and liver cancer, among others, but this is among the first meta-studies to make an association with the development of hematologic malignancies.

"I think when most people think about diabetes-related illnesses, they think of heart disease or kidney failure, but not necessarily cancer," lead author and hematologist/oncologist Jorge Castillo, M.D. "But when you consider that more than 19 million Americans have been diagnosed with diabetes not to mention the millions more who are either undiagnosed or will be diagnosed in the future a 20 percent increased risk of blood cancer is quite significant."

The meta-analysis included a look at 26 published research articles on the association between hematologic cancer incidence and type 2 diabetes, involving over 17,000 cases worldwide.

Specifically, they found increased incidence of peripheral T-cell lymphoma, leukemia, and myeloma among patients with type-2 diabetes, but no association with Hodgkin's lymphoma.

"It's important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise," Castillo said. "So by preventing the onset of type 2 diabetes, we could also prevent blood cancer."

Unfortunately, researchers have not identified the mechanism that associates type-2 diabetes with blood cancers and say that additional research is required to pinpoint that link.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap